115 related articles for article (PubMed ID: 38241878)
21. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
[TBL] [Abstract][Full Text] [Related]
22. Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer.
Steffen T; Dietrich D; Schnider A; Kettelhack C; Huber O; Marti WR; Furrer M; Gloor B; Schiesser M; Thierstein S; Brauchli P; Ruhstaller T;
Ann Surg; 2019 Jan; 269(1):83-87. PubMed ID: 28742685
[TBL] [Abstract][Full Text] [Related]
23. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
24. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.
Speicher PJ; Ganapathi AM; Englum BR; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
J Thorac Oncol; 2014 Aug; 9(8):1195-201. PubMed ID: 25157773
[TBL] [Abstract][Full Text] [Related]
25. Impact of pretreatment imaging on survival of esophagectomy after induction therapy for esophageal cancer: who should be given the benefit of the doubt?: esophagectomy outcomes of patients with suspicious metastatic lesions.
Erhunmwunsee L; Englum BR; Onaitis MW; D'Amico TA; Berry MF
Ann Surg Oncol; 2015 Mar; 22(3):1020-5. PubMed ID: 25234017
[TBL] [Abstract][Full Text] [Related]
26. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma.
Aboul-Enein MS; Knight W; Wulaningsih W; Foley DM; Dellaportas D; Zylstra J; Baker CR; Kelly M; Smyth E; Lagergren J; Maisey N; Allum WH; Gossage JA; Cunningham D; Davies AR;
J Surg Oncol; 2021 Dec; 124(8):1296-1305. PubMed ID: 34403501
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
28. [Surgical treatment and prognostic analysis of 109 patients with primary esophageal small cell carcinoma].
Zhang BH; Yang WJ; Zhao L; He J; Wang YG; Zhang HT
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):698-702. PubMed ID: 23159085
[TBL] [Abstract][Full Text] [Related]
29. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma.
Rucker AJ; Raman V; Jawitz OK; Voigt SL; Harpole DH; D'Amico TA; Tong BC
Ann Surg; 2022 Feb; 275(2):348-355. PubMed ID: 32209899
[TBL] [Abstract][Full Text] [Related]
31. Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
Swanson SJ; Batirel HF; Bueno R; Jaklitsch MT; Lukanich JM; Allred E; Mentzer SJ; Sugarbaker DJ
Ann Thorac Surg; 2001 Dec; 72(6):1918-24; discussion 1924-5. PubMed ID: 11789772
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy.
Tanaka E; Okabe H; Tsunoda S; Obama K; Kan T; Kadokawa Y; Akagami M; Sakai Y
Asian J Endosc Surg; 2012 Aug; 5(3):111-7. PubMed ID: 22776501
[TBL] [Abstract][Full Text] [Related]
33. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy.
Nieman DR; Peyre CG; Watson TJ; Cao W; Lunt MD; Lada MJ; Han MS; Jones CE; Peters JH
Ann Thorac Surg; 2015 Jan; 99(1):277-83. PubMed ID: 25442991
[TBL] [Abstract][Full Text] [Related]
36. The Role of Definitive Radiation and Surgery in Metastatic Esophageal Cancer: An NCDB Investigation.
Seyedin SN; Parekh KR; Ginader T; Caster JM
Ann Thorac Surg; 2021 Aug; 112(2):459-466. PubMed ID: 33096068
[TBL] [Abstract][Full Text] [Related]
37. Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer.
Speicher PJ; Wang X; Englum BR; Ganapathi AM; Yerokun B; Hartwig MG; D'Amico TA; Berry MF
Dis Esophagus; 2015; 28(8):788-96. PubMed ID: 25212528
[TBL] [Abstract][Full Text] [Related]
38. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
[TBL] [Abstract][Full Text] [Related]
39. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
40. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
